IMDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Insight Molecular Diagnostics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$2.89−0.12 (-3.99%)
Close on Oct 19, 2026
- Market cap
- $106.21M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2013 to 2025
Gross margin
56.7%+109.2 pts over 5 years
Operating margin
-1260.8%+1182.6 pts over 5 years
Net margin
-1238.5%+1223.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +115.6% | +61.8% | +27.2% | – | |
| Gross profit | +210.5% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -110.1% | -93.1% | 229.6% | |
| Return on assets | -82.2% | -62.8% | -165.1% | |
| Current ratio | 2.97 | 1.03 | 1.27 | |
| Capex to revenue | – | 100.9% | 78.5% | |
| Diluted shares | 1M | 0M | 30M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Insight Molecular Diagnostics generated $147.71M from operations and spent $10.57M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$147.71M
Used
$10.57M
Capital expenditure$10.57M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-1238.5%
×Asset turnover0.13×
×Equity multiplier-1.39×
=Return on equity, FY2025229.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -1238.5% | 0.13× | -1.39× | 229.6% |
| FY2024 | -3225.0% | 0.03× | 13.42× | -1480.7% |
| FY2023 | -1848.4% | 0.02× | 3.20× | -101.5% |
| FY2022 | -7609.8% | 0.01× | 2.61× | -146.5% |
| FY2021 | -2916.2% | 0.02× | 2.18× | -129.9% |
| FY2020 | -2461.5% | 0.03× | 1.48× | -93.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$50.22M
- Cash generatingOperating cash flow above zero-$22.18M
- Return on assets improvedROA up on the prior year-81.0% → -143.2%
- Earnings backed by cashOperating cash flow above net income-$22.18M vs -$50.22M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.62 → 1.27
- No dilutionShare count did not rise13M → 30M
- Gross margin improvedGross margin up on the prior year39.34% → 56.67%
- More efficientAsset turnover rose0.03 → 0.12